Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
“The approval of the two-milligram formulation of NARCAN® Nasal Spray provides an important new dosing option for patients at risk of severe opioid withdrawal, and demonstrates our ongoing commitment to support our commercialization partner, Adapt Pharma, with continued innovation in the area of opioid dependence,” said
NARCAN® Nasal Spray 4mg is a concentrated naloxone nasal spray indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. The 4mg formulation was approved by the
Indications and Important Safety Information: http://www.NarcanNasalSpray.com.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACT INFORMATION: Corporate Contact: Investor.email@example.com Media:
Susan FormanDGI firstname.lastname@example.org 212-825-3210 Investors: Glenn GarmontSenior Vice President Argot Partnersglenn@argotpartners.com 212-600-1902